{
    "clinical_study": {
        "@rank": "92684", 
        "arm_group": [
            {
                "arm_group_label": "1", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive doxorubicin IV over 5-15 minutes and cyclophosphamide IV over 5-60 minutes on day 1 every 3 weeks for 4 courses. Beginning 3 weeks after the last course of doxorubicin and cyclophosphamide, patients receive docetaxel IV over 1 hour every 3 weeks for 4 courses."
            }, 
            {
                "arm_group_label": "2", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive doxorubicin and cyclophosphamide as in arm I. Beginning 3 weeks after the last course of doxorubicin and cyclophosphamide, patients receive trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, and 15. Patients also receive docetaxel IV over 1 hour on day 2 for the first course and on day 1 for all subsequent courses. Treatment repeats every 3 weeks for 4 courses. After completion of the last course, patients continue to receive trastuzumab once weekly until 1 year from date of initial trastuzumab dose."
            }, 
            {
                "arm_group_label": "3", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive trastuzumab IV over 30-90 minutes on days 1, 8, and 15. Patients also receive docetaxel IV over 1 hour and carboplatin IV over 30-60 minutes on day 2 for the first course and on day 1 for all subsequent courses. Treatment repeats every 3 weeks for a total of 6 courses. After completion of the last course, patients continue to receive trastuzumab once weekly until 1 year from date of initial trastuzumab dose."
            }
        ], 
        "brief_summary": {
            "textblock": "Primary objective:\n\n        -  Compare disease-free survival in women with HER2-neu-expressing node-positive or\n           high-risk node-negative operable breast cancer treated with adjuvant doxorubicin,\n           cyclophosphamide, and docetaxel with or without trastuzumab (Herceptin) vs trastuzumab,\n           docetaxel, and carboplatin.\n\n      Secondary objective:\n\n        -  Compare overall survival of patients treated with these regimens.\n\n        -  Compare the toxic effects (including cardiac) of these regimens in these patients.\n\n        -  Compare quality of life of patients treated with these regimens.\n\n        -  Compare pathologic and molecular markers for predicting efficacy of these regimens in\n           these patients.\n\n        -  For substudy: Compare peripheral levels of shed HER2-neu extracellular domain with\n           fluorescence in situ hybridization in predicting outcome in patients treated with these\n           regimens."
        }, 
        "brief_title": "Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Histologically proven breast cancer with an interval between definitive surgery that\n             includes axillary lymph node involvement assessment and registration of less than or\n             equal to 60 days. A central pathology review may be performed post randomization for\n             confirmation of diagnosis and molecular studies. The same block used for her2neu\n             determination prior to randomization may be used for the central pathology review.\n\n          -  Definitive surgical treatment must be either mastectomy with axillary lymph node\n             involvement assessment, or breast conserving surgery with axillary lymph node\n             involvement assessment for operable breast cancer (T1-3, Clinical N0-1, M0). Margins\n             of resected specimen from definitive surgery must be histologically free of invasive\n             adenocarcinoma and/or ductal carcinoma in situ (DCIS).\n\n          -  Patients must be either lymph node positive or high risk node negative. Lymph node\n             positive patients will be defined as patients having invasive adenocarcinoma with at\n             least one axillary lymph node (pN1) showing evidence of tumor among a minimum of six\n             resected lymph nodes. High risk lymph node negative patients will be defined as\n             patients having invasive adenocarcinoma with either 0 (pNo) among a minimum of 6\n             resected lymph nodes or negative sentinel node biopsy (pNo) AND at least one of the\n             following factors: tumor size > 2 cm, ER and/or PR status is negative, histologic\n             and/or nuclear grade 2-3, or age < 35 years.\n\n          -  Tumor must show the presence of the her2neu gene amplification by Fluorescence\n             In-Situ Hybridization (FISH analysis) by a designated central laboratory.\n\n          -  Estrogen and/or progesterone receptor analysis performed on the primary tumor prior\n             to randomization. Results must be known at the time of randomization.\n\n          -  Karnofsky Performance status index \u2265 80%.\n\n          -  Normal cardiac function must be confirmed by LVEF (MUGA scan) and ECG within 3 months\n             prior to registration. The result of the MUGA must be equal to or above the lower\n             limit of normal for the institution.\n\n          -  Laboratory requirements: (within 14 days prior to registration)\n\n             a) Hematology: i) Neutrophils \u2265 2.0 109/L ii) Platelets \u2265 100 109/L iii) Hemoglobin \u2265\n             10 g/Dl\n\n             b) Hepatic function: i) Total bilirubin \u2264 1 UNL ii) ASAT (SGOT) and ALAT (SGPT) \u2264 2.5\n             UNL iii) Alkaline phosphatase \u2264 5 UNL iv) Patients with ASAT and/or ALAT > 1.5 x UNL\n             associated with alkaline phosphatase > 2.5 x UNL are not eligible for the study.\n\n             c) Renal function: i) Creatinine \u2264 175 \u00b5mol/L (2 mg/dL) ii) If limit reached, the\n             calculated creatinine clearance should be \u2265 60 mL/min.\n\n          -  Complete staging work-up within 3 months prior to registration. All patients will\n             have bilateral mammography, chest X-ray (PA and lateral) and/or CT and/or MRI,\n             abdominal ultrasound and/or CT scan and/or MRI, and bone scan. In cases of positive\n             bone scans, bone X-ray evaluation is mandatory to rule out the possibility of\n             metastatic bone scan positivity. Other tests may be performed as clinically\n             indicated.\n\n          -  Negative pregnancy test (urine or serum) within 7 days prior to registration for all\n             women of childbearing potential.\n\n          -  An audiology assessment with normal results will be performed within 4 weeks of\n             registration. This is only for those centers who have selected cisplatin as their\n             platinum salt of choice for the BCIRG 006 study.\n\n        Exclusion criteria:\n\n          -  Prior systemic anticancer therapy for breast cancer (immunotherapy, hormonotherapy,\n             chemotherapy).\n\n          -  Prior anthracycline therapy, taxoids (paclitaxel, docetaxel) or platinum salts for\n             any malignancy.\n\n          -  Prior radiation therapy for breast cancer.\n\n          -  Bilateral invasive breast cancer.\n\n          -  Pregnant, or lactating patients. Patients of childbearing potential must implement\n             adequate non-hormonal contraceptive measures during study treatment (chemotherapy and\n             tamoxifen therapy) and must have negative urine or serum pregnancy test within 7 days\n             prior to registration.\n\n          -  Any T4 or N2 or known N3 or M1 breast cancer.\n\n          -  Pre-existing motor or sensory neurotoxicity of a severity \u2265 grade 2 by NCI criteria.\n\n          -  Cardiac disease that would preclude the use of doxorubicin, docetaxel and Herceptin:\n\n               1. any documented myocardial infarction\n\n               2. angina pectoris that requires the use of antianginal medication\n\n               3. any history of documented congestive heart failure\n\n               4. Grade 3 or Grade 4 cardiac arrhythmia (NCI CTC, version 2.0)\n\n               5. clinically significant valvular heart disease\n\n               6. patients with cardiomegaly on chest x-ray or ventricular hypertrophy on ECG,\n                  unless they demonstrate by MUGA scan within the past 3 months that the LVEF is \u2265\n                  the lower limit of normal for the radiology facility;\n\n               7. patients with poorly controlled hypertension i.e. diastolic greater than 100\n                  mm/Hg. (Patients who are well controlled on medication are eligible for entry)\n\n               8. patients who currently receive medications (digitalis, beta-blockers, calcium\n                  channel-blockers, etc) that alter cardiac conduction, if these medications are\n                  administered for cardiac arrhythmia, angina or congestive heart failure. If\n                  these medications are administered for other reasons (ie hypertension), the\n                  patient will be eligible.\n\n          -  Other serious illness or medical condition:\n\n               1. history of significant neurologic or psychiatric disorders including psychotic\n                  disorders, dementia or seizures that would prohibit the understanding and giving\n                  of informed consent\n\n               2. active uncontrolled infection\n\n               3. active peptic ulcer, unstable diabetes mellitus\n\n               4. impaired hearing (only for those patients treated at centers who have selected\n                  cisplatin as their platinum salt of choice)\n\n          -  Past or current history of neoplasm other than breast carcinoma, except for:\n\n               1. curatively treated non-melanoma skin cancer\n\n               2. in situ carcinoma of the cervix\n\n               3. other cancer curatively treated and with no evidence of disease for at least 10\n                  years\n\n               4. ipsilateral ductal carcinoma in-situ (DCIS) of the breast\n\n               5. lobular carcinoma in-situ (LCIS) of the breast\n\n          -  Current therapy with any hormonal agent such as raloxifene, tamoxifen, or other\n             selective estrogen receptor modulators (SERMs), either for osteoporosis or\n             prevention. Patients must have discontinued these agents prior to randomization.\n\n          -  Chronic treatment with corticosteroids unless initiated > 6 months prior to study\n             entry and at low dose (\u2264 20 mg methylprednisolone or equivalent).\n\n          -  Concurrent treatment with ovarian hormonal replacement therapy. Prior treatment must\n             be stopped prior to randomization.\n\n          -  Definite contraindications for the use of corticosteroids.\n\n          -  Concurrent treatment with other experimental drugs. Participation in another clinical\n             trial with any investigational not marketed drug within 30 days prior to study entry.\n\n          -  Concurrent treatment with any other anti-cancer therapy.\n\n        The above information is not intended to contain all considerations relevant to a\n        patient's potential participation in a clinical trial."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "3150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 11, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_alias": "NCT00768092", 
            "nct_id": "NCT00021255", 
            "org_study_id": "TAX_GMA_302", 
            "secondary_id": "BCIRG 006"
        }, 
        "intervention": [
            {
                "arm_group_label": "1", 
                "description": "doxorubicine IV, cyclophosphamide IV, docetaxel IV", 
                "intervention_name": "doxorubicine, cyclophosphamide, docetaxel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "2", 
                "description": "doxorubicine IV, cyclophosphamide IV, trastuzumab IV, docetaxel IV", 
                "intervention_name": "doxorubicine, cyclophosphamide, trastuzumab, docetaxel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "3", 
                "description": "trastuzumab IV, docetaxel IV, carboplatin IV", 
                "intervention_name": "trastuzumab, docetaxel, carboplatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Docetaxel", 
                "Trastuzumab", 
                "Doxorubicin", 
                "Carboplatin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "September 19, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bridgewater", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "08807"
                    }, 
                    "name": "Sanofi-Aventis Administrative Office"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Buenos Aires", 
                        "country": "Argentina"
                    }, 
                    "name": "Sanofi-Aventis Administrative Office"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Macquarie Park", 
                        "country": "Australia"
                    }, 
                    "name": "Sanofi-Aventis Administrative Office"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vienna", 
                        "country": "Austria"
                    }, 
                    "name": "Sanofi-Aventis Administrative Office"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Diegem", 
                        "country": "Belgium"
                    }, 
                    "name": "Sanofi-Aventis Administrative Office"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sarajevo", 
                        "country": "Bosnia and Herzegovina"
                    }, 
                    "name": "Sanofi-Aventis Administrative Office"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sao Paulo", 
                        "country": "Brazil"
                    }, 
                    "name": "Sanofi-Aventis Administrative Office"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vazrjdane Region", 
                        "country": "Bulgaria"
                    }, 
                    "name": "Sanofi-Aventis Administrative Office"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Qu\u00e9bec", 
                        "country": "Canada"
                    }, 
                    "name": "Sanofi-Aventis Administrative Office"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bogota", 
                        "country": "Colombia"
                    }, 
                    "name": "Sanofi-Aventis Administrative Office"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zagreb", 
                        "country": "Croatia"
                    }, 
                    "name": "Sanofi-Aventis Administrative Office"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Praha", 
                        "country": "Czech Republic"
                    }, 
                    "name": "Sanofi-Aventis Administrative Office"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cairo", 
                        "country": "Egypt"
                    }, 
                    "name": "Sanofi-Aventis Administrative Office"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tallin", 
                        "country": "Estonia"
                    }, 
                    "name": "Sanofi-Aventis Administrative Office"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France"
                    }, 
                    "name": "Sanofi-Aventis Administrative Office"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Frankfurt", 
                        "country": "Germany"
                    }, 
                    "name": "Sanofi-Aventis Administrative Office"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kallithea", 
                        "country": "Greece"
                    }, 
                    "name": "Sanofi-Aventis Administrative Office"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hong Kong", 
                        "country": "Hong Kong"
                    }, 
                    "name": "Sanofi-Aventis Administrative Office"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Budapest", 
                        "country": "Hungary"
                    }, 
                    "name": "Sanofi-Aventis Administrative Office"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mumbai", 
                        "country": "India"
                    }, 
                    "name": "Sanofi-Aventis Administrative Office"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dublin", 
                        "country": "Ireland"
                    }, 
                    "name": "Sanofi-Aventis Administrative Office"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Natanya", 
                        "country": "Israel"
                    }, 
                    "name": "Sanofi-Aventis Administrative Office"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milan", 
                        "country": "Italy"
                    }, 
                    "name": "Sanofi-Aventis Administrative Office"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Sanofi-Aventis Administrative Office"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beirut", 
                        "country": "Lebanon"
                    }, 
                    "name": "Sanofi-Aventis Administrative Office"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Col. Coyoacan", 
                        "country": "Mexico"
                    }, 
                    "name": "Sanofi-Aventis Administrative Office"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Warsaw", 
                        "country": "Poland"
                    }, 
                    "name": "Sanofi-Aventis Administrative Office"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bucuresti", 
                        "country": "Romania"
                    }, 
                    "name": "Sanofi-Aventis Administrative Office"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Sanofi-Aventis Administrative Office"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bratislava", 
                        "country": "Slovakia"
                    }, 
                    "name": "Sanofi-Aventis Administrative Office"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ljubljana", 
                        "country": "Slovenia"
                    }, 
                    "name": "Sanofi-Aventis Administrative Office"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gauteng", 
                        "country": "South Africa"
                    }, 
                    "name": "Sanofi-Aventis Administrative Office"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain"
                    }, 
                    "name": "Sanofi-Aventis Administrative Office"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bromma", 
                        "country": "Sweden"
                    }, 
                    "name": "Sanofi-Aventis Administrative Office"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gen\u00e8ve", 
                        "country": "Switzerland"
                    }, 
                    "name": "Sanofi-Aventis Administrative Office"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taipei", 
                        "country": "Taiwan"
                    }, 
                    "name": "Sanofi-Aventis Administrative Office"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Megrine", 
                        "country": "Tunisia"
                    }, 
                    "name": "Sanofi-Aventis Administrative Office"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Istanbul", 
                        "country": "Turkey"
                    }, 
                    "name": "Sanofi-Aventis Administrative Office"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guildford Surrey", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Sanofi-Aventis Administrative Office"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montevideo", 
                        "country": "Uruguay"
                    }, 
                    "name": "Sanofi-Aventis Administrative Office"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Caracas", 
                        "country": "Venezuela"
                    }, 
                    "name": "Sanofi-Aventis Administrative Office"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Argentina", 
                "Australia", 
                "Austria", 
                "Belgium", 
                "Bosnia and Herzegovina", 
                "Brazil", 
                "Bulgaria", 
                "Canada", 
                "Colombia", 
                "Croatia", 
                "Czech Republic", 
                "Egypt", 
                "Estonia", 
                "France", 
                "Germany", 
                "Greece", 
                "Hong Kong", 
                "Hungary", 
                "India", 
                "Ireland", 
                "Israel", 
                "Italy", 
                "Korea, Republic of", 
                "Lebanon", 
                "Mexico", 
                "Poland", 
                "Romania", 
                "Russian Federation", 
                "Slovakia", 
                "Slovenia", 
                "South Africa", 
                "Spain", 
                "Sweden", 
                "Switzerland", 
                "Taiwan", 
                "Tunisia", 
                "Turkey", 
                "United Kingdom", 
                "Uruguay", 
                "Venezuela"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "Multicenter Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed By Docetaxel (AC-T) With Doxorubicin and Cyclophosphamide Followed By Docetaxel and Trastuzumab (Herceptin)(AC-TH) and With Docetaxel, Carboplatin and Trastuzumab (TCH) In The Adjuvant Treatment Of Node Positive and High Risk Node Negative Patients With Operable Breast Cancer Containing The HER2 Alteration", 
        "overall_official": {
            "affiliation": "Sanofi", 
            "last_name": "AUSSEL Jean Philippe", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Disease free survival", 
            "safety_issue": "No", 
            "time_frame": "calculated from the date of randomization up to the first date of local, regional, or distant relapse, second primary cancer (with the exception of curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix)"
        }, 
        "reference": {
            "PMID": "21991949", 
            "citation": "Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J; Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011 Oct 6;365(14):1273-83. doi: 10.1056/NEJMoa0910383."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00021255"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Overall survival", 
            "safety_issue": "No", 
            "time_frame": "measured from the date of randomization up to the date of death of any cause."
        }, 
        "source": "Sanofi", 
        "sponsors": {
            "collaborator": {
                "agency": "Cancer International Research Group", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2001", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }, 
    "geocoordinates": {
        "Sanofi-Aventis Administrative Office": "10.491 -66.902"
    }
}